Daily profiles of plasma phenylalanine and tyrosine in patients with osteogenic sarcoma during treatment with high-dose methotrexate-citrovorum rescue

1989 ◽  
Vol 17 (4) ◽  
pp. 265-270 ◽  
Author(s):  
Mary A. Hilton ◽  
Salvatore Bertolone ◽  
Chandrakant C. Patel
Keyword(s):  
Osteogenic Sarcoma ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Plasma Phenylalanine ◽  
Dose Methotrexate

Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy.

1983 ◽  
Vol 1 (4) ◽  
pp. 251-254 ◽  
Author(s):  
N Jaffe ◽  
E Smith ◽  
H T Abelson ◽  
E Frei
Keyword(s):  
Adjuvant Chemotherapy ◽  
Median Time ◽  
Pulmonary Metastases ◽  
Osteogenic Sarcoma ◽  
Median Number ◽  
Control Group ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Dose Methotrexate ◽  
Age And Sex

The number and time to appearance of pulmonary metastases were evaluated in 15 patients with osteogenic sarcoma receiving adjuvant chemotherapy with high-dose methotrexate and doxorubicin (adjuvant group). The results were compared to 33 age- and sex-matched controls (control group). The adjuvant group demonstrated a reduction in the number and a delay in the appearance of the metastases. The median time to development of metastases was 17 mo in the adjuvant group and 7 mo in the control group, and the median number of metastases was 2 and 12, respectively.

Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma

1994 ◽  
Vol 5 (4) ◽  
pp. 480-482 ◽  
Author(s):  
Mee-Chou Klu ◽  
Chuang-Chl Liaw ◽  
Tsai-Shen Yang ◽  
Gi-Ming Lai ◽  
Shin-Nun Hsl ◽  
...  
Keyword(s):  
Osteogenic Sarcoma ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Dose Methotrexate

81 HIGH-DOSE METHOTREXATE TREATMENT IN CHILDREN WITH OSTEOGENIC SARCOMA

1995 ◽  
Vol 17 (4) ◽  
pp. 402
Author(s):  
A Wiela-Hojeńska ◽  
K Orzechowska-Juzwekom ◽  
M Slociak ◽  
J Unolt ◽  
M Hurkacz ◽  
...  
Keyword(s):  
Osteogenic Sarcoma ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Dose Methotrexate ◽  
Methotrexate Treatment

Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma

1994 ◽  
Vol 33 (5) ◽  
pp. 420-424 ◽  
Author(s):  
T. Pignon ◽  
B. Lacarelle ◽  
F. Duffaud ◽  
P. Guillet ◽  
J. Catalin ◽  
...  
Keyword(s):  
Osteogenic Sarcoma ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Dose Methotrexate

scholarly journals High dose methotrexate therapy for a case with osteogenic sarcoma. I. Consideration for safety administration.

1986 ◽  
Vol 32 (3) ◽  
pp. 516-523
Author(s):  
Hiroki GOTOH ◽  
Makoto YOSHIYA ◽  
Osamu OHSHIMA ◽  
Kazuyuki OHTSUKA ◽  
Yohichi KURACHI ◽  
...  
Keyword(s):  
Osteogenic Sarcoma ◽  
Methotrexate Therapy ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Dose Methotrexate

Plasma phenylalanine: Tyrosine ratios during high-dose methotrexate-citrovorum “rescue”

1982 ◽  
Vol 10 (4) ◽  
pp. 389-395 ◽  
Author(s):  
Mary A. Hilton ◽  
Chandrakant C. Patel ◽  
Salvatore J. Bertolone ◽  
Donald R. Kmetz ◽  
Larry W. Clark
Keyword(s):  
High Dose ◽  
High Dose Methotrexate ◽  
Plasma Phenylalanine ◽  
Dose Methotrexate

High-dose methotrexate: a critical reappraisal.

1987 ◽  
Vol 5 (12) ◽  
pp. 2017-2031 ◽  
Author(s):  
S P Ackland ◽  
R L Schilsky
Keyword(s):  
Clinical Investigation ◽  
Plasma Concentrations ◽  
Osteogenic Sarcoma ◽  
Clinical Situation ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Treatment Regimens ◽  
Dose Methotrexate ◽  
Metabolic Block ◽  
Childhood Acute Leukemia

High-dose methotrexate (HDMTX) with leucovorin (LV) rescue has been used as a therapeutic strategy in oncology for more than a decade. Administration of HDMTX results in tumoricidal plasma concentrations of the drug without significant host toxicity, provided that plasma MTX levels are monitored and LV rescue is properly administered. The original premise of LV rescue was that the provision of reduced folate to normal cells would circumvent the metabolic block produced by MTX and allow resumption of DNA synthesis, although the presumed therapeutic selectivity of leucovorin has not yet been adequately explained. Despite a strong pharmacologic rationale and a vast clinical experience, HDMTX with leucovorin rescue has not been shown to be unequivocally superior to conventional doses of MTX in any clinical situation except, perhaps, for treatment of osteogenic sarcoma and childhood acute leukemia. While HDMTX is an important component of effective treatment regimens for these diseases, its precise contribution to the success of these regimens remains undefined. Although HDMTX can theoretically overcome all known mechanisms of MTX resistance, no data exist to suggest that this can be accomplished in the clinic. Thus, this well-known but poorly understood treatment regimen must remain a subject of clinical investigation rather than a part of routine clinical practice.

Sign in / Sign up

Export Citation Format

Share Document